KR101630466B1 - Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체 - Google Patents

Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체 Download PDF

Info

Publication number
KR101630466B1
KR101630466B1 KR1020107025218A KR20107025218A KR101630466B1 KR 101630466 B1 KR101630466 B1 KR 101630466B1 KR 1020107025218 A KR1020107025218 A KR 1020107025218A KR 20107025218 A KR20107025218 A KR 20107025218A KR 101630466 B1 KR101630466 B1 KR 101630466B1
Authority
KR
South Korea
Prior art keywords
thieno
dihydro
pyridin
hydroxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107025218A
Other languages
English (en)
Korean (ko)
Other versions
KR20100137563A (ko
Inventor
다니엘 크라보
프랑끄 르삐쁘레
소피 알라꿔-보제끄
크리스띤 샤롱
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101630466(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20100137563A publication Critical patent/KR20100137563A/ko
Application granted granted Critical
Publication of KR101630466B1 publication Critical patent/KR101630466B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107025218A 2008-04-11 2009-03-17 Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체 Expired - Fee Related KR101630466B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290364 2008-04-11
EP08290364.2 2008-04-11

Publications (2)

Publication Number Publication Date
KR20100137563A KR20100137563A (ko) 2010-12-30
KR101630466B1 true KR101630466B1 (ko) 2016-06-14

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025218A Expired - Fee Related KR101630466B1 (ko) 2008-04-11 2009-03-17 Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체

Country Status (25)

Country Link
US (1) US8563729B2 (enExample)
EP (1) EP2262500B1 (enExample)
JP (1) JP5592348B2 (enExample)
KR (1) KR101630466B1 (enExample)
CN (1) CN101998853B (enExample)
AU (1) AU2009235784B2 (enExample)
BR (1) BRPI0910439B8 (enExample)
CA (1) CA2721025C (enExample)
CO (1) CO6300954A2 (enExample)
DK (1) DK2262500T3 (enExample)
EA (1) EA017756B1 (enExample)
EC (1) ECSP10010599A (enExample)
ES (1) ES2584278T3 (enExample)
HR (1) HRP20160907T1 (enExample)
HU (1) HUE027857T2 (enExample)
IL (1) IL208067A (enExample)
MX (1) MX2010011047A (enExample)
MY (1) MY155836A (enExample)
NZ (1) NZ589136A (enExample)
PL (1) PL2262500T3 (enExample)
PT (1) PT2262500T (enExample)
SI (1) SI2262500T1 (enExample)
UA (1) UA103321C2 (enExample)
WO (1) WO2009124636A1 (enExample)
ZA (1) ZA201008050B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009243811B2 (en) * 2008-05-05 2014-04-10 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
ES2445537T3 (es) * 2009-12-29 2014-03-03 Poxel Activadores de tieno[2,3-b]piridinadiona de AMPK y usos terapéuticos de los mismos
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011121109A1 (en) 2010-04-02 2011-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2809492C (en) 2010-09-01 2018-12-18 Bayer Cropscience Ag Herbicidally active ketosultams and diketopyridines
JP2014507452A (ja) * 2011-03-07 2014-03-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー キノリン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
EP3322711B1 (en) 2015-06-25 2021-03-10 University Health Network Hpk1 inhibitors and methods of using same
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
BR112021009270A2 (pt) * 2018-11-16 2021-08-10 Poxel sal de potássio mono-hidratado de um derivado de tienopiridona e seu processo de preparação
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
BR112022018731A2 (pt) 2020-03-26 2022-11-01 Poxel Uso de um derivado de tienopiridona no tratamento de adrenoleucodistrofia ou adrenomieloneuropatia
MX2022012350A (es) * 2020-04-02 2022-10-27 Poxel Uso de un derivado de tienopiridona en el tratamiento de poliquistosis renal autosomica dominante (adpkd).
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
CA3238252A1 (en) 2021-11-19 2023-05-25 Amit Choudhary Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2007019914A1 (en) 2005-08-18 2007-02-22 Merck Patent Gmbh Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA903588B (en) 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CA2714181C (en) 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Ampk modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2007019914A1 (en) 2005-08-18 2007-02-22 Merck Patent Gmbh Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BRPI0910439B1 (pt) 2020-10-20
BRPI0910439B8 (pt) 2021-05-25
MX2010011047A (es) 2010-10-26
CO6300954A2 (es) 2011-07-21
US20110034505A1 (en) 2011-02-10
IL208067A (en) 2015-05-31
MY155836A (en) 2015-12-15
EP2262500A1 (en) 2010-12-22
EA017756B1 (ru) 2013-02-28
ECSP10010599A (es) 2010-12-30
UA103321C2 (ru) 2013-10-10
SI2262500T1 (sl) 2016-09-30
JP2011516510A (ja) 2011-05-26
DK2262500T3 (en) 2016-08-15
NZ589136A (en) 2012-06-29
PT2262500T (pt) 2016-08-16
EA201001585A1 (ru) 2011-06-30
CA2721025C (en) 2016-07-26
US8563729B2 (en) 2013-10-22
ES2584278T3 (es) 2016-09-26
ZA201008050B (en) 2011-07-27
HRP20160907T1 (hr) 2016-09-23
KR20100137563A (ko) 2010-12-30
HUE027857T2 (en) 2016-11-28
EP2262500B1 (en) 2016-04-27
JP5592348B2 (ja) 2014-09-17
IL208067A0 (en) 2010-12-30
AU2009235784B2 (en) 2013-09-19
PL2262500T3 (pl) 2016-09-30
WO2009124636A1 (en) 2009-10-15
AU2009235784A1 (en) 2009-10-15
CN101998853B (zh) 2015-02-11
BRPI0910439A2 (pt) 2015-09-29
HK1155955A1 (en) 2012-06-01
CA2721025A1 (en) 2009-10-15
CN101998853A (zh) 2011-03-30

Similar Documents

Publication Publication Date Title
KR101630466B1 (ko) Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체
KR101648593B1 (ko) Ａｍｐ-활성화된 단백질 키나아제 (ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체
KR101641391B1 (ko) 퀴녹살린디온 유도체
EP2519527B1 (en) Thieno[2,3-b]pyridinedione activators of ampk and therapeutic uses thereof
HK1155955B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
HK1156313B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190516

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240609

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240609